Investigation of the Metabolism, Excretion and Pharmacokinetics of an Openlabel Single Dose of 300 mg [14C]Volasertib Administered Intravenously in Patients With Various Solid Tumours With a Possible Extension Phase With Nonlabelled Drug
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2013
At a glance
- Drugs Volasertib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 15 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 15 Nov 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.